STOCK TITAN

[Form 4] CHEMED CORP Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Chemed Corp (CHE) reported an insider equity award. CEO and Director Kevin J. McNamara received a grant of stock options covering 58,672 shares on 10/21/2025, with an exercise price of $443.79 per share. The options expire on 10/21/2030 and vest in three equal annual installments starting 10/21/2026. Following this award, he directly holds 266,159 derivative securities. No non-derivative transactions were listed in the excerpt.

Chemed Corp (CHE) ha riferito un premio azionario riservato agli insider. Il CEO e Direttore Kevin J. McNamara ha ricevuto una concessione di opzioni su azioni che coprono 58.672 azioni il 21/10/2025, con un prezzo di esercizio di 443,79 $ per azione. Le opzioni scadono il 21/10/2030 e vestono in tre rate annuali uguali a partire dal 21/10/2026. A seguito di questa concessione, detiene direttamente 266.159 titoli derivati. Nessuna transazione non derivata era elencata nell'estratto.

Chemed Corp (CHE) informó una adjudicación de acciones para insiders. El CEO y Director Kevin J. McNamara recibió una concesión de opciones sobre acciones que cubren 58.672 acciones el 21/10/2025, con un precio de ejercicio de 443,79 $ por acción. Las opciones expiran el 21/10/2030 y vesten en tres tramos anuales iguales a partir del 21/10/2026. Tras esta adjudicación, posee directamente 266.159 valores derivados. No se detallaron transacciones no derivadas en el extracto.

Chemed Corp (CHE)가 내부자 주식 보상을 보고했습니다. CEO 겸 이사인 Kevin J. McNamara는 2025년 10월 21일에 58,672주를 커버하는 주식옵션을 받았고 행사가격은 주당 443.79달러입니다. 이 옵션은 2030년 10월 21일에 만료되며 2026년 10월 21일부터 매년 3등분으로 동일하게 vesting됩니다. 이 보상 이후 그는 직접 266,159개의 파생증권을 보유합니다. 발췌문에 비파생거래는 기재되지 않았습니다.

Chemed Corp (CHE) a annoncé une attribution d'actions pour informations internes. Le PDG et administrateur Kevin J. McNamara a reçu une attribution d'options d'achat d'actions couvrant 58 672 actions le 21/10/2025, avec un prix d'exercice de 443,79 $ par action. Les options expireront le 21/10/2030 et vestent en trois tranches annuelles égales à partir du 21/10/2026. À la suite de cette attribution, il détient directement 266 159 titres dérivés. Aucune transaction non dérivée n'était répertoriée dans l'extrait.

Chemed Corp (CHE) meldete eine Insider-Aktienzuweisung. Der CEO und Direktor Kevin J. McNamara erhielt am 21.10.2025 eine Zuweisung von Aktienoptionen über 58.672 Aktien bei einem Ausübungspreis von 443,79 $ pro Aktie. Die Optionen verfallen am 21.10.2030 und vesten in drei gleichen jährlichen Tranchen ab dem 21.10.2026. Nach dieser Zuweisung hält er direkt 266.159 derivative Wertpapiere. Im Auszug wurden keine Nicht-Derivatstransaktionen aufgeführt.

Chemed Corp (CHE) أبلغت عن مكافأة أسهم داخلية. تلقّى الرئيس التنفيذي والمدير Kevin J. McNamara منحة خيارات أسهم تغطي 58,672 سهماً في 21/10/2025، مع سعر ممارسة قدره 443.79 دولاراً للسهم. تنتهي صلاحية الخيارات في 21/10/2030 وتكتسب تدريجياً على ثلاث دفعات سنوية متساوية ابتداءً من 21/10/2026. بعد هذه المنحة، يمتلك مباشرة 266,159 ورقة مالية مشتقة. لم تُذكر أية معاملات غير مشتقة في المقتطف.

Positive
  • None.
Negative
  • None.

Chemed Corp (CHE) ha riferito un premio azionario riservato agli insider. Il CEO e Direttore Kevin J. McNamara ha ricevuto una concessione di opzioni su azioni che coprono 58.672 azioni il 21/10/2025, con un prezzo di esercizio di 443,79 $ per azione. Le opzioni scadono il 21/10/2030 e vestono in tre rate annuali uguali a partire dal 21/10/2026. A seguito di questa concessione, detiene direttamente 266.159 titoli derivati. Nessuna transazione non derivata era elencata nell'estratto.

Chemed Corp (CHE) informó una adjudicación de acciones para insiders. El CEO y Director Kevin J. McNamara recibió una concesión de opciones sobre acciones que cubren 58.672 acciones el 21/10/2025, con un precio de ejercicio de 443,79 $ por acción. Las opciones expiran el 21/10/2030 y vesten en tres tramos anuales iguales a partir del 21/10/2026. Tras esta adjudicación, posee directamente 266.159 valores derivados. No se detallaron transacciones no derivadas en el extracto.

Chemed Corp (CHE)가 내부자 주식 보상을 보고했습니다. CEO 겸 이사인 Kevin J. McNamara는 2025년 10월 21일에 58,672주를 커버하는 주식옵션을 받았고 행사가격은 주당 443.79달러입니다. 이 옵션은 2030년 10월 21일에 만료되며 2026년 10월 21일부터 매년 3등분으로 동일하게 vesting됩니다. 이 보상 이후 그는 직접 266,159개의 파생증권을 보유합니다. 발췌문에 비파생거래는 기재되지 않았습니다.

Chemed Corp (CHE) a annoncé une attribution d'actions pour informations internes. Le PDG et administrateur Kevin J. McNamara a reçu une attribution d'options d'achat d'actions couvrant 58 672 actions le 21/10/2025, avec un prix d'exercice de 443,79 $ par action. Les options expireront le 21/10/2030 et vestent en trois tranches annuelles égales à partir du 21/10/2026. À la suite de cette attribution, il détient directement 266 159 titres dérivés. Aucune transaction non dérivée n'était répertoriée dans l'extrait.

Chemed Corp (CHE) meldete eine Insider-Aktienzuweisung. Der CEO und Direktor Kevin J. McNamara erhielt am 21.10.2025 eine Zuweisung von Aktienoptionen über 58.672 Aktien bei einem Ausübungspreis von 443,79 $ pro Aktie. Die Optionen verfallen am 21.10.2030 und vesten in drei gleichen jährlichen Tranchen ab dem 21.10.2026. Nach dieser Zuweisung hält er direkt 266.159 derivative Wertpapiere. Im Auszug wurden keine Nicht-Derivatstransaktionen aufgeführt.

Chemed Corp (CHE) أبلغت عن مكافأة أسهم داخلية. تلقّى الرئيس التنفيذي والمدير Kevin J. McNamara منحة خيارات أسهم تغطي 58,672 سهماً في 21/10/2025، مع سعر ممارسة قدره 443.79 دولاراً للسهم. تنتهي صلاحية الخيارات في 21/10/2030 وتكتسب تدريجياً على ثلاث دفعات سنوية متساوية ابتداءً من 21/10/2026. بعد هذه المنحة، يمتلك مباشرة 266,159 ورقة مالية مشتقة. لم تُذكر أية معاملات غير مشتقة في المقتطف.

Chemed Corp(CHE)披露了内部人股权奖励。 首席执行官兼董事 Kevin J. McNamara 于2025年10月21日获得覆盖58,672股的股票期权授予,行权价为每股443.79美元。该等期权将于2030年10月21日到期,并将于2026年10月21日起分三次等额归属。此项奖励后,他直接持有266,159份衍生证券。摘录中未列出任何非衍生交易。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MCNAMARA KEVIN J

(Last) (First) (Middle)
2600 CHEMED CENTER
255 EAST 5TH STREET

(Street)
CINCINNATI OH 45202

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CHEMED CORP [ CHE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
president and CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy with tandem tax withholding) $443.79 10/21/2025 A 58,672 (1) 10/21/2030 Capital Stock 58,672 $443.79 266,159 D
Explanation of Responses:
1. Vesting in three equal annual installments commencing 10/21/2026
Kevin J. McNamara 10/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CHE’s CEO report on Form 4?

Kevin J. McNamara reported a grant of stock options covering 58,672 shares.

What is the exercise price of the CHE stock options?

The exercise price is $443.79 per share.

When do the CHE options vest for the CEO?

They vest in three equal annual installments starting 10/21/2026.

What is the expiration date of the options?

The options expire on 10/21/2030.

How many derivative securities does the CEO hold after the grant?

He holds 266,159 derivative securities directly after this transaction.

Were there any reported stock sales or purchases of common shares?

The excerpt shows no non-derivative transactions listed.

What is CHE’s ticker symbol?

Chemed Corp trades under the symbol CHE.
Chemed Corp

NYSE:CHE

CHE Rankings

CHE Latest News

CHE Latest SEC Filings

CHE Stock Data

6.34B
14.29M
1.98%
97.98%
2.82%
Medical Care Facilities
Services-home Health Care Services
Link
United States
CINCINNATI